Trailing Twelve Months Revenue Growth: Oncternal Corp (ONCT)

Public company logo of oncternal.com (ONCT)

Oncternal Therapeutics is penetrating the solid and hematologic tumor therapy market, leveraging unique patents in receptor inhibitors. This daily price chart of the 12-month revenue trajectory on the GURU.Markets portal shows the value has stabilized at -65.40. Positive catalysts include the success of zilovertamab in treating lymphomas, the development of CAR-T technologies, and support from specialized institutions.

Oncternal Therapeutics (ONCT): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 02/20/2024

Oncternal Therapeutics - analytical breakdowns and key metrics (ONCT)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Oncternal
Brand item of Oncternal Corp

To objectively evaluate the issuer, it is essential for the manager to track revenue dynamics over the last twelve months, where daily growth recalculations allow for the differentiation of random fluctuations from a systemic decline. Analyzing the annual growth rate of trailing twelve-month (LTM) revenue is critical for Oncternal Therapeutics (ONCT), as geopolitical tensions and sanction-related logistics restrictions for reagents could slow the market launch of drugs, which would be reflected in this indicator.

Who Oncternal Therapeutics competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Trailing Twelve Months Sales Growth|KZIA: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Silexion Therapeutics|NuCana plc (NCNA) - Sales Growth YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) Chimerix, Inc|Revenue Growth YoY (Last 12 Months) CYCC|Revenue Growth YoY (Last 12 Months) G1 Therapeutics (GTHX)|Sales Growth YoY (Last Twelve Months) Kronos Bio Corporation (KRON)|Kintara - Sales Growth YoY (Last 12 Months)|Portage Biotech - Revenue Growth YoY (Last 12 Months)